Tariff uncertainty widens
What happened
Companies are still reshaping supply‑chain plans around tariff risk, and a recent executive order could impose tariffs up to 100% on some patented imported drugs—adding another layer of trade volatility. Coverage notes both the lingering business impact of prior tariff moves and emerging, sector‑specific tariff steps that can prompt import timing changes (cnbc.com) (ksbw.com) (statnews.com).
Why it matters
On April 2, 2026, the White House issued an order that raises duties on certain patented medicines and the ingredients used to make them to as much as 100%, while offering lower or zero tariffs for drugmakers that sign new U.S. pricing agreements or commit to build manufacturing in the United States. (whitehouse.gov) The proclamation invokes a 1962 trade statute to justify the duties and phases the implementation so some large companies face the new tariffs in about 120 days and smaller companies in about 180 days, and the administration has negotiated three‑year tariff exemptions with a group of major manufacturers including Pfizer, Eli Lilly and Novo Nordisk among roughly 16 companies that have publicly announced deals. (foleyhoag.com) (money.usnews.com) Companies and logistics operators are already changing flows and timing because of tariff risk: importers scrambled to accelerate shipments into the Port of Los Angeles in previous tariff rounds, and trade reporting shows firms building inventories and delaying replenishment strategies ahead of known duty deadlines. (webpronews.com) (cnbc.com) The administration’s pricing deals use a “most‑favored‑nation” approach — a pledge by a company to match the lowest price it charges in other wealthy countries — and that pledge has been the basis for many of the three‑year tariff exemptions negotiated with specific manufacturers. (whitehouse.gov) (bloomberg.com) Logistics real‑estate consequences are already visible: Prologis’ management told investors that customers are likely to raise inventory levels and look for overflow storage and flexible short‑term space, and operators are considering bonded warehouses and foreign‑trade‑zone solutions to delay or avoid tariff hits. (supplychaindive.com) (msn.com) Market indicators remain mixed in Southern California: an industry index reported expanded available warehouse capacity alongside low utilization readings in late 2025, while regional real‑estate reporting has shown rising vacancy pressure in the Inland Empire compared with prior years — a pattern that creates uneven pockets of demand for temporary storage versus long‑term leases. (its4logistics.com) (commercialobserver.com)
Key numbers
- Companies are still reshaping supply‑chain plans around tariff risk, and a recent executive order could impose tariffs up to 100% on some patented imported drugs—adding another layer of trade volatility.
- On April 2, 2026, the White House issued an order that raises duties on certain patented medicines and the ingredients used to make them to as much as 100%, while offering lower or zero tariffs for drugmakers that sign new U.S.
- (its4logistics.com) (commercialobserver.com)
What happens next
- (its4logistics.com) (commercialobserver.com) Companies are still reshaping supply‑chain plans around tariff risk, and a recent executive order could impose tariffs up to 100% on some patented imported drugs—adding another layer of trade volatility.
Quick answers
What happened in Tariff uncertainty widens?
Companies are still reshaping supply‑chain plans around tariff risk, and a recent executive order could impose tariffs up to 100% on some patented imported drugs—adding another layer of trade volatility. Coverage notes both the lingering business impact of prior tariff moves and emerging, sector‑specific tariff steps that can prompt import timing changes (cnbc.com) (ksbw.com) (statnews.com).
Why does Tariff uncertainty widens matter?
On April 2, 2026, the White House issued an order that raises duties on certain patented medicines and the ingredients used to make them to as much as 100%, while offering lower or zero tariffs for drugmakers that sign new U.S. pricing agreements or commit to build manufacturing in the United States. (whitehouse.gov) The proclamation invokes a 1962 trade statute to justify the duties and phases the implementation so some large companies face the new tariffs in about 120 days and smaller companies in about 180 days, and the administration has negotiated three‑year tariff exemptions with a group of major manufacturers including Pfizer, Eli Lilly and Novo Nordisk among roughly 16 companies that have publicly announced deals. (foleyhoag.com) (money.usnews.com) Companies and logistics operators are already changing flows and timing because of tariff risk: importers scrambled to accelerate shipments into the Port of Los Angeles in previous tariff rounds, and trade reporting shows firms building inventories and delaying replenishment strategies ahead of known duty deadlines. (webpronews.com) (cnbc.com) The administration’s pricing deals use a “most‑favored‑nation” approach — a pledge by a company to match the lowest price it charges in other wealthy countries — and that pledge has been the basis for many of the three‑year tariff exemptions negotiated with specific manufacturers. (whitehouse.gov) (bloomberg.com) Logistics real‑estate consequences are already visible: Prologis’ management told investors that customers are likely to raise inventory levels and look for overflow storage and flexible short‑term space, and operators are considering bonded warehouses and foreign‑trade‑zone solutions to delay or avoid tariff hits. (supplychaindive.com) (msn.com) Market indicators remain mixed in Southern California: an industry index reported expanded available warehouse capacity alongside low utilization readings in late 2025, while regional real‑estate reporting has shown rising vacancy pressure in the Inland Empire compared with prior years — a pattern that creates uneven pockets of demand for temporary storage versus long‑term leases. (its4logistics.com) (commercialobserver.com)
